New Developments in Liposomal Drug Delivery


Authors: B.S. Pattni, V.V. Chupin and V.P. Torchilin

Journal: Chemical Reviews

DOI: 10.1021/acs.chemrev.5b00046

Publication - Abstract

October 14, 2015

Abstract:


Described first in the 1960s by Bangham1 and understood as a potential drug delivery system in the early 1970s,2−4 the liposome has since become integral to research and clinical applications in the field of nanomedicine. Five decades of research in the field of liposome research have shown their prospective benefits in the medical and cosmetic5−7 as well as the food industry.8,9 Several promising small molecule drugs and genes previously deemed less than useful due to problems of stability, solubility, and nonspecific toxicity can now be delivered to the intended sites of action with the help of nanocarriers like micelles, nanoparticles, and liposomes.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Lipid Nanoparticles of Type-A CpG D35 Suppress Tumor Growth by Changing Tumor Immune-microenvironment and Activate CD8 T Cells in Mice

L. Munakata, Y. Tanimoto, A. Osa, J. Meng, Y. Haseda, Y. Naito, H. Machiyama, A. Kumanogoh, D. Omata, K. Maruyama, Y. Yoshioka, Y. Okada, S. Koyama, R. Suzuki, and T. Aoshi

Type-A CpG oligodeoxynucleotides (ODNs), which have a natural phosphodiester backbone, is one of the highest IFN-α inducer from plasmacytoid dendritic cells (pDC) via Toll-like receptor 9 (TLR9)-dependent signaling. However, the in vivo application of Type-A CpG has been li...
Read More


Publication - Abstract

Synthesis of Protein Conjugates Adsorbed on Cationic Liposomes Surface

D. Chatzikleanthous, R. Cunliffe, F. Carboni, M.R. Romano, D.T. O'Hagan, C.W. Roberts, Y. Perrie and R. Adamo

The well-known Toll like receptor 9 (TLR9) agonist CpG ODN has shown promising results as vaccine adjuvant in preclinical and clinical studies, however its in vivo stability and potential systemic toxicity remain a concern. In an effort to overcome these issues...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.